AstraZeneca Pharma India Limited — Important, 18-11-2024: General Updates

AstraZeneca Pharma India Limited is set to launch Breztri Aerosphere, a combination inhalation preparation consisting of Budesonide, Glycopyrronium, and Formoterol, in January 2025. This product will be available following the receipt of Import and Market Permission from the Drugs Controller General of India. Breztri Aerosphere is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients, aiming to relieve symptoms and prevent exacerbations. The introduction of this new therapy could enhance the company's product portfolio and potentially boost its market position in respiratory care. Investors should monitor this development closely as it may lead to positive growth opportunities in the upcoming financial periods.